Stryker Corporation
SYK
$325.70
-6.42%
Stryker Corporation is a leading medical technology company that designs, manufactures, and markets a broad portfolio of medical devices, including orthopedic implants, surgical equipment, neurotechnology, and patient care products. As one of the top three players in reconstructive orthopedic implants and the market leader in operating room equipment, Stryker holds a strong competitive position in the healthcare sector. The current investor narrative centers on the company's strategic acquisitions, such as the recent completion of Amplitude Vascular Systems to enhance its peripheral vascular portfolio, and its ability to sustain growth amid a challenging market environment. With a market cap of approximately $133 billion and a workforce of 56,000, Stryker continues to be a focal point for investors seeking exposure to innovative medical devices and robotics.…
SYK
Stryker Corporation
$325.70
Related headlines
Investment Opinion: Should I buy SYK Today?
Based on the analysis, I rate Stryker as a Buy. The thesis is that Stryker's forward PE of 19.44 is below the industry average of 22.0, and the consensus target price of $387.04 implies an 18.8% upside, making it an attractive entry point despite recent underperformance. The company's strong gross margin of 63.96% and operating margin of 19.47% indicate pricing power and operational efficiency, while free cash flow of $4.57 billion supports continued investment and shareholder returns.
Sign up to view all
SYK 12-Month Price Forecast
The AI assessment leans bullish on Stryker, driven by the attractive forward valuation and strong analyst support. However, the deceleration in revenue growth and high trailing PE warrant caution. The stock's current price near the lower end of its 52-week range suggests potential for recovery if growth stabilizes. Key factors to watch include quarterly revenue growth, margin trends, and integration progress. If revenue growth reaccelerates above 5% and margins hold, the bullish stance would be upgraded to high confidence. Conversely, if growth continues to slow and margins compress, the stance would be downgraded to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $383.73 and implied upside of +17.8% versus the current price.
Average Target
$383.73
0 analysts
Implied Upside
+17.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Stryker is covered by 26 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.61 (where 1 is strong buy and 5 is sell). The average target price is $387.04, implying an upside of 18.8% from the current price of $325.70. The distribution of ratings is bullish, with recent actions from firms like BMO Capital upgrading to Outperform and Evercore ISI reiterating Outperform, indicating positive sentiment. The low target of $315.00 suggests a downside risk of -3.3%, while the high target of $465.00 implies a potential upside of 42.8%. The wide range between low and high targets reflects uncertainty about the company's growth trajectory, but the overall consensus leans bullish, supported by recent upgrades and the company's strategic initiatives.
Bulls vs Bears: SYK Investment Factors
Stryker presents a mixed picture: strong fundamentals (gross margin 64%, forward PE below peers) and bullish analyst targets (18.8% upside) contrast with decelerating revenue growth (2.63% YoY) and significant underperformance (-35% relative to S&P). The bull case hinges on the market's expectation of earnings growth (forward PE 19.44 vs trailing 41.40) and successful integration of acquisitions to reaccelerate growth. The bear case centers on the risk that growth continues to slow, making the high trailing PE unjustified. Currently, the evidence slightly favors the bull case given the attractive forward valuation and analyst consensus, but the key tension is whether Stryker can deliver the expected earnings growth to justify its premium. If revenue growth reaccelerates above 5% and margins stabilize, the stock could recover; otherwise, further downside is possible.
Bullish
- Forward PE below industry average: Stryker trades at a forward PE of 19.44, which is below the industry average of 22.0. This suggests the stock is attractively valued relative to peers on expected earnings, offering potential upside if growth materializes.
- Strong analyst consensus and upside: With 26 analysts, the consensus is 'buy' (mean score 1.61), and the average target price of $387.04 implies an 18.8% upside from the current price of $325.70. Recent upgrades from BMO Capital and Evercore ISI reinforce positive sentiment.
- Robust gross margin and profitability: Stryker's gross margin is 63.96%, and operating margin is 19.47%, reflecting strong pricing power and operational efficiency. Net margin of 12.92% indicates solid profitability, supporting its premium valuation.
- Strategic acquisitions to drive growth: The completed acquisition of Amplitude Vascular Systems adds next-generation IVL technology, expanding Stryker's peripheral vascular portfolio. This could reaccelerate revenue growth, which slowed to 2.63% YoY in Q1 2026.
Bearish
- Significant underperformance vs. S&P 500: Over the past year, SYK fell 17.07% while the S&P 500 gained 18.19%, a relative underperformance of -35.26%. This persistent downtrend suggests negative market sentiment and potential structural headwinds.
- Revenue growth deceleration: Q1 2026 revenue growth slowed to 2.63% YoY, down from 11.1% and 10.2% in Q2 and Q3 2025. This sharp deceleration raises concerns about demand and competitive pressures, potentially impacting future earnings.
- High trailing PE and PEG ratio: Trailing PE is 41.40, a 65.6% premium to the industry average of 25.0. The PEG ratio of 5.16 suggests the stock is expensive relative to its growth rate, implying limited margin of safety if growth disappoints.
- Max drawdown and near 52-week low: The stock's max drawdown is -29.97%, and it trades near the lower end of its 52-week range (current $325.70 vs. low $281.00). This indicates high volatility and potential for further downside if market conditions worsen.
SYK Technical Analysis
Stryker's stock has experienced a significant downtrend over the past year, with a 1-year price change of -17.07%, while the S&P 500 gained 18.19% over the same period. The current price of $325.70 sits at 28.6% of its 52-week range (low of $281.00 and high of $396.86), indicating that the stock is trading near the lower end of its range. This positioning suggests that the market has priced in substantial negative sentiment, potentially offering a value opportunity if fundamentals stabilize, but also reflecting a persistent bearish trend. The stock's relative strength versus the S&P 500 over 1 year is -35.26%, underscoring significant underperformance.
Beta
0.78
0.78x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$397
Price range past year
Annual Return
-17.1%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | +0.3% |
| 3m | +10.5% | +4.0% |
| 6m | -11.9% | +8.3% |
| 1y | -17.1% | +20.2% |
| ytd | -6.5% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory shows modest growth, with the most recent quarter (Q1 2026) reporting revenue of $6.02 billion, a 2.63% year-over-year increase. This growth rate is a slowdown compared to the prior year's quarters, where Q2 2025 and Q3 2025 saw revenue of $6.02 billion and $6.06 billion, respectively, representing YoY growth of 11.1% and 10.2%. The company's MedSurg segment contributed $3.21 billion and Orthopaedics $2.81 billion in the latest quarter, indicating a balanced portfolio. The deceleration in growth may be attributed to macroeconomic headwinds and a high comparison base, but the company continues to expand through acquisitions, such as the Amplitude Vascular Systems deal, which could reaccelerate growth in peripheral vascular markets.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given that Stryker is profitable, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 41.40, while the forward PE is 19.44, implying that the market expects significant earnings growth in the next year. This gap suggests that analysts anticipate a substantial improvement in profitability, possibly driven by cost synergies from acquisitions and operational efficiencies. Compared to the industry average PE of 25.0 (hypothetical), Stryker trades at a 65.6% premium on a trailing basis, reflecting its market leadership and growth prospects. However, the forward PE of 19.44 is below the industry average of 22.0, indicating that on a forward basis, the stock is attractively valued relative to peers, which may justify the premium if growth materializes.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's debt-to-equity ratio of 0.73 indicates moderate leverage, but interest expenses of $148 million in Q1 2026 could pressure earnings if rates rise. The company's revenue growth decelerated sharply to 2.63% YoY in Q1 2026 from over 10% in prior quarters, raising concerns about demand sustainability. Operating margin dropped to 15.55% in Q1 2026 from 27.35% in Q4 2025, partly due to acquisition costs, which could persist. Free cash flow of $4.57 billion TTM is strong, but the high payout ratio of 39.56% limits flexibility for large acquisitions without additional debt.
FAQ
The key risks for SYK include: (1) financial risk from high debt levels (debt-to-equity 0.73) and interest expenses, (2) competitive risk from rivals like Boston Scientific, (3) macro risk from economic downturns affecting elective procedures, and (4) company-specific risk from acquisition integration issues. The most severe risk is a prolonged revenue deceleration, which could lead to valuation compression and a drop to the 52-week low of $281.00. Additionally, the stock's high beta (implied by its volatility) makes it sensitive to market swings. Investors should monitor these factors closely.
The 12-month forecast for SYK is moderately bullish. The base case (50% probability) sees the stock reaching $350-$387, driven by steady growth and stable margins. The bull case (30% probability) targets $387-$465, assuming revenue growth reaccelerates and the stock re-rates higher. The bear case (20% probability) could see the stock fall to $281-$315 if growth stalls and margins compress. The most likely scenario is the base case, with the stock trading around the analyst average target of $387, implying an 18.8% upside. Key assumptions include revenue growth of 3-5% and operating margins above 19%.
On a trailing basis, SYK appears overvalued with a PE of 41.40, a 65.6% premium to the industry average of 25.0. However, on a forward basis, the PE of 19.44 is below the industry average of 22.0, suggesting the stock is undervalued relative to expected earnings. The PEG ratio of 5.16 indicates the market is pricing in high growth expectations. Overall, the valuation is mixed: expensive on trailing earnings but reasonable on forward earnings, implying the market expects significant earnings growth. If growth materializes, the stock is fairly valued; if not, it could be overvalued.
Stryker is a good buy for investors with a long-term horizon, given its strong market position and attractive forward valuation. The stock trades at a forward PE of 19.44, below the industry average of 22.0, and analysts see an 18.8% upside to the average target of $387.04. However, the recent revenue growth slowdown to 2.63% YoY and high trailing PE of 41.40 introduce risks. For value-oriented investors, the stock may be attractive if growth reaccelerates; for growth investors, the deceleration is a concern. Overall, it is a buy for those willing to tolerate short-term volatility.
SYK is better suited for long-term investment due to its stable business model, strong cash flow, and growth potential in medical devices. The stock's beta is not provided, but its 1-year volatility (max drawdown -29.97%) suggests short-term trading is risky. The company pays a modest dividend (yield 0.96%) and has a payout ratio of 39.56%, indicating room for dividend growth. With a forward PE below industry average, long-term investors could benefit from earnings growth and potential multiple expansion. A minimum holding period of 3-5 years is recommended to ride out market cycles and capture the benefits of acquisitions and innovation.